SCHEMBL3530684

SCHEMBL3530684

Cc1ccnc(Oc2cccc3[nH]nc(-c4nc5ccc(N6CCN(C)CC6)cc5[nH]4)c23)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 12/20 0.58
FLT1 P17948 6/20 0.58
ALDH1A1 P00352 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
KDM4E B2RXH2 2/20 0.47
NPC1 O15118 1/20 0.47
POLB P06746 1/20 0.47
RAB9A P51151 1/20 0.47
CDK4 P11802 2/20 0.47
CCNA2 P20248 1/20 0.47
CCND1 P24385 1/20 0.47
CDK2 P24941 1/20 0.47
CCND3 P30281 1/20 0.47
KDR P35968 5/20 0.46
PDGFRB P09619 3/20 0.46
PDGFRA P16234 2/20 0.46
FGFR2 P21802 2/20 0.46
FGFR4 P22455 2/20 0.46
FGFR3 P22607 2/20 0.46
MEN1 O00255 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3540584 0.90 FGFR1 (0.62) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3536899 0.88 FGFR1 (0.60) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3534844 0.87 FGFR1 (0.69) FGFR1FLT1KDRABL1BCR
SCHEMBL3536656 0.84 FGFR1 (0.59) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3545063 0.84 FGFR1 (0.68) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3538587 0.83 FGFR1 (0.62) FGFR1FLT1KDRPDGFRAFGFR2
SCHEMBL3534332 0.83 FGFR1 (0.61) FGFR1FLT1ALDH1A1SMN1; SMN2CDK4
SCHEMBL3540627 0.82 FGFR1 (0.65) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3540067 0.82 FGFR1 (0.56) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL3537451 0.81 FGFR1 (0.53) FGFR1FLT1ALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885ALDH1A1 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.